China’s sovereign debt is becoming a strategic alternative to US Treasuries: economist



China’s sovereign debt is emerging as a strategic alternative to US Treasuries as global investors look for geopolitical hedges, though greater market liquidity and deeper yuan internationalisation are still needed to cement its status as a global safe haven, an economist at a Chinese government think tank has said.

“[These bonds] circumvent the restrictions of the non-convertibility of the renminbi,” said Xu Qiyuan, deputy director of the American Studies Institute at the Chinese Academy of Social Sciences, in a February report.

“At the same time, they possess high-grade sovereign credit backing and liquidity and minimise the risk of sanctions or asset freezes due to holding assets within the major US financial system, such as US Treasury bonds.”

Xu’s comments came at a time of swirling debate in Chinese policy circles about how Beijing can capitalise on wavering investor confidence in the United States and the US dollar. The issue is expected to be a hot topic at the “two sessions” – the annual meetings of China’s top legislature and advisory body – beginning on Wednesday.

Xu said geopolitical hedges aligned with a strategic push by sovereign institutions to diversify their asset allocations. This demand was being further fuelled by a shortage of high-quality liquid assets, despite relatively abundant global liquidity, he added.

He cited the robust demand for Beijing’s US$4 billion dollar-denominated sovereign bonds issued in Hong Kong last November – which matched the US’ borrowing costs for the first time – as an example.

  • Related Posts

    China’s EV battery leader CATL to step up use of AI in R&D, founder and chairman says

    The founder and chairman of Contemporary Amperex Technology Ltd (CATL) said his company plans to ramp up the use of artificial intelligence in research and take Chinese battery technology and…

    Continue reading
    China biotech outlicensing tops US$52 billion in first 2 months after global deal surge

    The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *